Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKDB-501A in Post-stroke Upper Limb Spasticity
NCT05382767Phase 1Completed
- Sponsor
- CKD BiO
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Microbial Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKDB-501 in post-stroke upper limb spasticity (PSS) (2 arms), sponsored by CKD BiO. Primary endpoint: Incidence of Adverse Events. Started Jun 2022; status: completed.
02
Drugs
CKDB-501
03
Conditions
post-stroke upper limb spasticity (PSS)
Beyond the preview
Go deeper on NCT05382767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382767.